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blocking virus interactions with co-receptors C-C chemokine-receptor 5 (CCR5) and CXC chemokine-receptor 95 4 (CXCR4) (22, 27) . The authors observed that NF279 could bind and block receptor signaling and arrest HIV-96 1 fusion downstream of CD4 binding prior to engagement of coreceptor. Our data implicate early HIV-1 fusion 97 events and we sought here to determine the mechanism of fusion inhibition by probing the role of HIV-1 98 envelope (Env) interaction with the P2X1 antagonists.
100
Here, we examined the activities of P2X1 antagonists on HIV-1 productive infection in order to determine the 101 impact on HIV-1 fusion, the impact on neutralization of HIV-1 expressing various Env sequences, and the site 102 of localization on HIV-1 Env where these drugs inhibit. We demonstrate that two drugs selective for P2X1, 103 NF279 and NF449, can neutralize a diverse panel of HIV-1 viruses with differing IC 50 values and that treatment 104 with NF449 can alter Env accessibility and impact the access of broadly neutralizing antibodies, specifically 105 targeting the V1V2 region of HIV-1 Env. These data indicate that P2X1 antagonists can interfere with HIV-1 106 Env directly, potentially altering the binding of HIV-1 and inhibiting interaction with coreceptor (CCR5/CXCR4) 107 that mediates HIV-1 fusion. This study provides the compelling suggestion that P2X1 antagonists could be 108 used as an adjuvant strategy to alter HIV-1 envelope accessibility in the interest of vaccine and therapeutic 
116
A panel of antagonists was tested for dose-dependent inhibition of infection of HIV-1 NL-CI (NL4-3 Cherry 117 internal ribosome entry site), an X4-tropic virus with the fluorescent mCherry protein expressed in place of Nef 118 (28) . Azidothymidine (AZT), the nucleoside reverse transcriptase inhibitor, and pyridoxalphosphate-6-119 azophenyl-2′,4′-disulfonic acid tetrasodium salt (PPADS), a non-selective P2 antagonist that we observed 120 previously to inhibit HIV-1 infection in MT4 cells (23), were compared to a variety of P2X1 and P2X7 selective 121 antagonists in the MT4 cell line (Figure 1, Table 1 ). IC 50 inhibitory values are indicated where applicable. The 122 most compounds in this model were P2X1 antagonists NF279 and NF449, which inhibited HIV-1 at IC 50 values 123 of 0.88 μM and 0.23 μM, respectively, as compared with AZT, which had an IC 50 value of 0.01 μM. Both NF279 124 and NF449 were more potent than PPADS (IC 50 = 4.7 μM). A438079 is a P2X7 inhibitor that did not 125 demonstrate inhibitory capability ≥ 50%. Other P2X7 selective drugs including A804598, A839977, 126 AZ11645373, A740003, AZ10606120, GW791343, JNJ479655567, and Ro 0437626 did not inhibit NL-CI 127 infection in MT4 cells. For almost all compounds, minimal toxicity was observed with the exception of 10-20% 128 cell toxicity resulting from 100 μM NF279 treatment and >50% toxicity resulting from 100 μM AZ10606120 or 129 Ro 0437626 treatment.
131
Kinetics of NF279 and NF449 inhibition confirm their activity on HIV-1 Env-mediated fusion.
133
Our previous studies implicated NF279 and other P2X antagonists as HIV-1 fusion inhibitors in cell-to-cell and 134 cell-free infection (23, 25) . Here, we assessed whether the above antagonists were similarly active as HIV-1 135 fusion inhibitors. We employed a HIV-1 Gag-iCre cell-based viral entry assay, in which Cre-recombinase is 136 packaged into the HIV-1 virion and target indicator cells undergo a Cre-activated red-to-green (RG) switch 137 upon HIV-1 fusion (25, 26) . We observed that both NF279 and NF449 inhibited 100% HIV-1 fusion at 100 μM, 138 while A438079 partially inhibited fusion at 100 μM (Figure 2A ). Dose response curves indicated a dose-139 dependent inhibition of HIV-1 fusion by NF279 and NF449, while partial inhibition by A438079 was below 25% 140 for all concentrations tested ( Figure 2B ).
142
We next performed time-of-addition experiments ( Figure 2C ) in which these drugs were added at different 143 hours post-infection (HPI) to verify whether they acted on the virus fusion step or later stages in the viral life 144 cycle (29, 30) . Virus attachment and virus-cell fusion were expected between 0-2 HPI, reverse transcription 145 was expected at 3-4 HPI, integration was expected near 6 HPI, transcription, RNA export, translation and 146 assembly were expected between 10-16 HPI, and budding and maturation were expected after 16 HPI (29, 147 30). We hypothesized that the P2X1 antagonists would inhibit early viral life cycle events contemporaneous 148 with AMD3100, a CXCR4 antagonist that inhibits viral membrane fusion at 2 HPI. In contrast, AZT is known to 149 act on reverse transcription and was expected to inhibit HIV-1 productive infection when added prior to 4 HPI.
150
MT4 cells were infected with HIV-1 NL-CI and drugs were added at 0, 2, 4, and 24 HPI. We observed that 151 several P2X1 antagonists did not inhibit or weakly inhibited including A438079 and A804598 (not shown), while 152 AMD3100 inhibited at the same time-point as NF279 and NF449, confirming that these drugs inhibit viral 153 replication at the stage of viral membrane fusion. Addition of NF279, NF449, or AMD3100 after 4 HPI did not 154 inhibit infection, as HIV-1 fusion would have already occurred. As expected, addition of AZT prior to 4 HPI 155 resulted in near complete inhibition of infection, while addition of AZT after 4 HPI did not result in inhibition of 156 infection, as reverse transcription had already occurred. We concluded that NF279 and NF449 block HIV-1 157 infection at same stage of the HIV-1 virus life cycle as the fusion inhibitor, AMD3100.
159
Contribution of gp41 to HIV-1 inhibition by NF279 and NF449.
161
It has been hypothesized that P2X1 or P2X7 antagonism through receptor interaction might represent the 162 mechanism of fusion inhibition. Our laboratory and others have demonstrated a dearth of receptor expression 163 on the surface of infected cells as well as a body of data suggesting interaction and activation of coreceptor 164 (22, 27, 31) . We therefore probed the interaction of drug directly on HIV-1 envelope.
166
HIV-1 viral membrane fusion is mediated by HIV-1 envelope glycoproteins gp120 and gp41. Binding of gp120 167 to CD4 and coreceptor activates a fusogenic function of gp41 by exposing the N-terminal fusion peptide which 168 allows for cell membrane insertion and generation of a pre-hairpin intermediate structure that bridges viral and 169 target cell membranes ((32-37) . Given our previous results which suggests that NF279 and NF449 block HIV-1 170 fusion, we tested whether they interacted with HIV-1 Env gp41. First, we examined whether the role of gp41 171 pre-hairpin structure was required for fusion inhibition by NF279, NF449, and A438079. To test this, we used 172 enfuvirtide (also known as T-20), a 36-residue alpha peptide fusion inhibitor that binds to the pre-hairpin 173 structure of gp41, thereby inhibiting viral membrane fusion (32-34, 38, 39) . We assessed the role of pre-174 treatment with T-20 on inhibition of productive infection by NF279, NF449, and A438079. We reasoned that T-175 20-abrogation of the effect of NF279, NF449, or A438079 inhibition would indicate a role for the gp41 hairpin 176 structure in the nature of this interaction. Figure 3A shows the effect of each drug on inhibition of HIV-1 177 productive infection in the presence (colored bars) or absence (50% opacity colored bars) of T-20 is shown. T-20 was used at a concentration (0.1 μg/ml) that on its own caused 50% inhibition without added drug. T-20 179 treatment resulted in some inhibition at NF279 0.5 μM and 1 μM but not at 5 μM and this did not mean 180 significance. No effect was noted for NF449 or A438089 or for AZT as would be expected. This suggested that 181 NF449 and likely NF279 antagonism is not dependent on the pre-hairpin structure of gp41.
182 183 Subsequently, we tested the P2X1 antagonists for inhibition of infection in MT4 cells by a C-terminal truncation 184 of HIV-1 Env gp41 (NL-CICT). This mutant enhances Env fusogenicity and has been shown to regulate 185 exposure of Env epitopes to neutralizing antibodies by modulating Env structural conformation (35, 36, 40) . We 186 hypothesized that if P2X1 antagonists bind directly to Env, their inhibitory potencies would be modulated by the 187 CT mutation. Dotted lines indicate inhibition of NL-CI infection based with IC 50 values based on Figure 1 and 188 Table 1 . We observed that NF279 inhibition was shifted from an IC 50 of 1.0 μM for NL-CI to 1.8 μM for NL-189 CICT ( Figure 3B ). NF449 inhibition was shifted from an IC 50 of 0.2 μM to 2.7 μM, nearly 5-fold. By contrast, 190 no appreciable difference in inhibition was noted for A430879. The NF279 and NF449 data demonstrate 191 altered inhibition of HIV-1 infection that results from the conformational changes of Env induced by the CT 192 mutation, indicating that these P2X1 antagonists confer HIV-inhibitory activity by directly interacting with Env.
194
NF449 inhibits a strain of CXCR4-tropic virus more efficiently than a strain of CCR5-tropic virus in 195 primary cells.
197
We next evaluated the impact of these drugs on inhibition of viral replication on various types of Envs to 198 understand the spectrum of inhibition of these drugs, not only against laboratory-adapted strains but also 199 clinical isolates based on prior observations that non-selective inhibitors could reduce both R5 and S4-tropic 200 virus (23). To test physiological relevance, we compared inhibition of these viruses in human peripheral blood 201 mononuclear cells (PBMCs), and in particular, we looked at transmitted/founder (T/F) viruses.
202
Transmitted/founder (T/F) viruses arise from the propagation of a single virus strain in a naïve host and 203 represent the variants transmitted in human HIV-1 infections We first tested the effect of P2X1 antagonists on 204 replication of the laboratory-adapted HIV-1 NL4-3 (NL-CI, X4-tropic) virus vs. RHPA (NL-CI-11036, T/F R5-205 tropic The inhibition of NF449 and A438079 was compared to PPADS and AZT ( Figure 4 ). In the presence of 206 the X4-tropic virus, AZT inhibited productive infection to near 90%, PPADS inhibited infection to near 60%, 207 NF449 inhibited near 75%, and A438079 inhibited 35%, which is lower than 50% inhibition observed for MT4 208 cells ( Figure 1 ). For R5-tropic viral inhibition, the drugs targeting P2X receptors had decreased inhibitory 209 activity when compared to X4-tropic viral inhibition. NF449 had an IC 50 of 33 μM and a maximal inhibition near 210 45% as compared with PPADS with an IC 50 at 21 μM and a maximal inhibition near 50%. A438079 failed to 211 inhibit either virus above 50%, even at maximal concentrations. By contrast, AZT showed no significant change 212 in inhibitory activity between X4-and R5-trophic infection of human PBMCs. We concluded that NF449 is an 213 effective inhibitor of productive infection in primary cells with inhibition favoring X4-tropic viral infection. 214 215 NF279 and NF449 inhibition is dependent on Env sequence.
217
Next, we tested the P2X1 antagonists for inhibition of infection by HIV-1 expressing different Env variants, 218 including T/F Env strains. We hypothesized that if the P2X1 selective antagonists do interact with Env during 2), SF162 (Clade B, chronic R5-tropic, Tier 1), DU172 (Clade C, T/F R5-tropic, Tier 2). These were selected to 225 allow for a comparison of chronic and transmitted founder viruses of various clades. NF279 inhibited all viruses 226 to 100%, with IC 50 values between 0.04 μM and 50 μM. Of note, NF279 was remarkably potent against DU172, 227 a molecular clone that is highly resistant to broadly neutralizing antibodies ( Figures 5A and 5C ). NF449 228 inhibited all viruses, except SF162, to nearly 100% at 100 μM, with IC 50 values ranging from 3 μM to >30 μM 229 across clades. A438079 had the least effective inhibition profile with a maximal inhibition of NL4-3 to 40% at 230 100 μM. Additionally, we looked at the effect of reducing multiplicity of infection (MOI) for the different viruses 231 when treated with NF279 and NF449. For infection with NL4-3, RHPA, REJO, and DU172, no difference was 232 noted in inhibition with varied MOI. For SF162, inhibition by NF279 and NF449 was greatest at low MOI 233 whereas with increased MOI, inhibition was reduced. These data demonstrate the drug potencies vary across 234 different viral Env constructs. This suggests that P2X1 antagonist activity is Env strain-dependent. 235 236 NF449 inhibition interferes with a V1V2-specific monoclonal antibody against HIV-1 Env.
238
Given the observation that variations in HIV-1 Env sequence altered NF279 and NF449 inhibition, we wished 239 to determine the region of HIV-1 envelope likely to be involved in this inhibition by looking for functional 240 interactions with the activity of a panel of broadly neutralizing antibodies (bNAbs) ( Figure 6A ). We tested 241 bNAbs targeting several regions of HIV-1 envelope (see Figure 6B ), 2F5 (MPER on gp41), PG9 (gp120 V1V2 242 apex), 2G12 (gp120 glycan), and VRC01 (gp120 CD4-binding site). mCherry-expressing NL-CI virus was 243 treated with drug (NF279, NF449, or AZT) followed by bNAb, and then added to MT4 cells.
245
Each of the drugs and bNAbs was tested at a concentration close to their respective IC 50 . After 48 hours, cells 246 were fixed and analyzed by flow cytometry to quantify infection based on mCherry expression. We 247 hypothesized that if a drug interferes with bNAb binding to Env, virus inhibition will be dampened relative to 248 that observed with a non-interfering drug. A heatmap is shown ( Figure 6B ) demonstrating the inhibition of 249 infection by drug and/or bNAb as compared to untreated infected cells. While it was expected that viral 250 inhibition would be reduced with a non-interfering drug, it was observed that treatment with PG9 and NF449 251 resulted in full abrogation of inhibition. This suggested that NF449 antagonized the PG9 binding site, gp120 252 V1V2. Furthermore, titrations of NF449 at a fixed dose of PG9 ( Figure 6C ) demonstrated higher levels of 253 infection in cells treated with both NF449 and PG9, supporting the notion that NF449 may block the ability of 254 PG9 to bind to HIV-1 Env, either directly or indirectly through interaction and modification of the PG9 binding 255 site, and that this interaction may account for the ability of NF449 to inhibit viral membrane fusion.
257
To further explore the hypothesis that NF449 activity is dependent on directly binding to, or changing the 258 conformation of the HIV-1 Env V1V2 region at the PG9 binding site, we employed a well-characterized 259 antibody binding system (41) (42) (43) . This system retains viral particles on the surface of HIV-infected CD4 T cells 260 based on tetherin-high expression, allowing for the enhanced resolution of differences in antibody binding. We 261 incubated HIV-1 infected cells at 37°C in the presence of increasing concentrations of NF449. Prior to 262 conducting binding experiments, residual NF449 was washed off and Ab binding experiments were conducted 263 at 4°C. We observed that PG9 binding to HIV-1 Env was significantly reduced in the presence of increasing 264 concentrations of NF449, as compared to binding of 2G12, VRC01, and 2F5 binding ( Figure 6D ). The highest 265 level of inhibition was observed at 50 μM where PG9 binding inhibition was noted at 66% as compared to 266 2G12 inhibition of 41%, VRC01 inhibition of 33%, and 2F5 inhibition of 9%.
268
Taken together, these observations demonstrate modulation of NF449 fusion inhibition by Env-specific bNAbs 269 and differing Env variants, suggesting that Env plays a role in P2X1 antagonist inhibition of HIV-1 infection.
270
The observation that NF449 and PG9 antagonize inhibition suggests that NF449 may binding directly to gp120 271 at the region of V1V2 or allosteric changes to the Env structure may prevent PG9 access to Env V1V2. These 272 may impact on interaction with coreceptor critical to mediate viral membrane fusion.
274 Discussion

276
Here we demonstrate that several P2X1 antagonists can block HIV-1 infection, and that the inhibition (1) 277 interferes at the level of viral membrane fusion (2) favors X4-tropic virus (3) relies on intact gp41 and (4) 278 demonstrates varied activity against diverse clades. This activity may specifically interfere with Env, as NF279 279 and NF449 interfere with antibody accessibility at the V1V2 region of gp120. In Figure 1 , it was demonstrated 280 that NF279 and NF449 inhibit infection at micromolar concentrations, with IC 50 values lower than for the non-281 selective inhibitor PPADS. A438079 had minimal inhibition and the other drugs tested did not interfere with 282 HIV-1 productive infection. 283 284 NF279 and NF449 inhibited viral membrane fusion, consistent with our prior observations (25). A time-of 285 addition experiment indicated that both NF279 and NF449 both inhibit HIV-1 replication before 4 HPI, 286 concurrent with AMD3100 inhibition but distinct from AZT activity that works later in the virus life cycle. These 287 data further support the notion that these P2X1 antagonists block HIV-1 infection at the level of viral membrane 288 fusion. It is important to note that NF279, NF449 and A438079 may have activity against both P2X1 and P2X7.
289
NF279 and NF449 have greater selectivity for P2X1 and A438079 has greater selectivity for P2X7 (44-51); 290 however, the concentrations tested in this study are much higher than the range where they act as selective 291 antagonists, and therefore, the observations cannot definitively distinguish the affected receptor subtypes 292 (Table 1) . It is important to note that even at the highest concentrations, viability of cells was not affected.
294
A cross titration experiment was performed to determine whether treatment with enfurvutide (T-20) 295 inhibition would be impacted by NF279 or NF449 treatment as the mechanism of T-20 activity is based on 296 binding of the pre-hairpin structure of gp41 to inhibit fusion ( Figure 3A ). We reasoned that if the drugs have 297 similar mechanisms, coordinated treatment with T-20 and NF279 or NF449 would competitively antagonized 298 inhibition of HIV-1 infection. Our observations did not support this as no difference was noted between NF279 299 or NF449 treated samples and those treated with NF279 or NF449 plus T-20. These data suggest that NF279 300 and NF449 may have an alternative mechanism to engage Env. We then tested the hypothesis that HIV-1 Env 301 conformation might play a role in virus fusion inhibition by these drugs by evaluating the effect of a C-terminal 302 truncation mutant of gp41 (NL-CIΔCT) that open the HIV-1 Env structure to expose neutralizing Ab epitopes.
303
Virus inhibition was shifted slightly for NF279 but nearly 5-fold for NF449, indicating higher resistance of 304 altered Env exposure to inhibition by NF449 ( Figure 3B ). This observation may be explained by a different 305 conformation of Env that is induced by the gp41 mutation to result in altered binding affinity of the drugs, which 306 is demonstrated by a change in the slope of NF449 inhibition curves against NL-CI versus NL-CIΔCT (52).
307
A438079 demonstrated no change in its inhibition against NL-CI compared to NL-CIΔCT, suggesting that the 308 effects seen with NF279 and NF449 are specific to these two drugs (52).
310
To assess HIV-1 inhibition in physiologically relevant cells, we compared NF279, NF449, and A438079 311 were to AZT for the ability to inhibit HIV-1 productive infection in human PBMCs (Figure 4) , We observed 312 inhibition by both NF279 and NF449, with greater activity of NF449 against of X4-tropic virus than R5-tropic 313 virus, and minimal overall activity of A4388079. NF279 and NF449 were also compared to A438079 across a 314 variety of HIV-1 envelopes ( Figure 5 ). NF279 maintained the lowest IC 50 values of the three compounds with 315 only modest increases in IC 50 between NL4-3 and RPHA envelope. The CXCR4-tropic virus was more 316 sensitive to NF449 inhibition than CCR5-tropic virus, which suggests envelope specificity; however, NF279 and 317 NF449 inhibited a range of envelopes suggesting that the nature of the inhibition may be through direct binding 318 to Env. It is notable that NF449 inhibited SF162 less than other viruses, while NF279 inhibited DU172 to a 319 much greater extent. Neutralization of SF162 by NF449 may relate to Env variable loop 2 (V2) glycosylation 320 and interference with CD4 and co-receptor interactions (53) . Highly effective inhibition of DU172 by NF279 321 suggests that these compounds may be potential therapeutic options for highly resistant viruses. In Figure 5B ,
322
MOI titrations indicate minimal change in inhibition in all viral clones with the exception of NF449 in which 323 increasing the MOI to 1 reduces infection nearly completely with NF449, suggesting the ability of that clone to 324 compete out the effect of inhibition.
326
Based on evidence that varied HIV-1 Env clones had different responses to NF279 and NF449 inhibition, 327 we sought to map the region of inhibition by testing the effect of treatment with NF279 and NF449 on of a 328 panel of bNABs for their ability to inhibit HIV-1 infection ( Figure 6 ). Our observation indicated that PG9 329 inhibition was significantly reduced in the presence of NF449 in a dose-dependent manner. These 330 observations suggest that NF449 may inhibit HIV-1 Env at the region of V1V2 where PG9 binds. Furthermore, 331 the co-administration of NF449 and PG9 negated the effect of inhibition, suggesting an allosteric interaction at 332 the site of V1V2 or director interaction between drug and antibody, reducing effective binding and 333 neutralization of HIV-1.
335
We observed in an in vitro system, NF279 and NF449 but not A438079, can effectively block HIV-1 336 replication at the level of viral membrane fusion ( Figure 2 ). Both compounds are most effective at inhibiting X4-337 tropic HIV-1 infection, but are effective inhibitors against multiple HIV-1 envelopes. However, NF279 and 338 NF449 are suramin-derivatives, which are large molecules that may not be optimal for therapeutic 339 development for the following reasons. Therapeutic options that target P2X receptors for pharmaceutical 340 development would include those agents that follow Lipinski's parameter thresholds (54, 55) : molecular weight 341 of less than 500 kDA, lipophilicity (octanol-water partial coefficient) logP <5, no more than 10 hydrogen bond 342 acceptors, and no more than 5 hydrogen bond donors. The values for IC 50 reported in Figure 1 are higher than 343 those IC 50 values reported for P2X1 inhibition (44-46, 49-51, 56-69) . This may reflect that the drug 344 concentrations tested have effects that target not only the receptor but other cellular events such as the direct 345 binding of HIV-1 Env. It will be of benefit to test more compounds with P2X1 and P2X7 activity that satisfy 346 these pharmaceutical requirements for potential clinical development. By contrast to NF279 and NF449, 347 A438079 did not demonstrate inhibition of HIV-1 fusion. Interestingly, A438079 has previously been 348 demonstrated to have differential inhibition of HIV-1 productive infection in cell lines vs. in human lymphoid 349 aggregate cultures (24). This may reflect a different mechanism of inhibition from the P2X1 antagonists and will 350 be the subject of future investigation.
351
352 Giroud et al. (22) have demonstrated that NF279 can antagonize signaling of CCR5 and CXCR4 and 353 conclude that this drug and other drugs function to inhibit HIV-1 fusion through interferences with functional 354 engagement of CCR5 and CXCR4 by HIV-1 Env. These studies indicate inhibition of fusion through co-355 receptor binding and through antagonism of calcium signaling stimulated by gp120. Several studies implicate 356 the role of V1V2 in CXCR4 and CCR5 interaction (37, (70) (71) (72) . In an uninhibited setting, HIV-1 fusion occurs 357 through Env, a trimeric glycoprotein with three copies of the gp120 subunit and three copies of the membrane-358 anchored gp41 subunit. The gp120 subunit binds to the host cell CD4 which induces conformational changes 359 that expose the binding site of coreceptor (CCR5/CXCR4) and this mobilizes the gp41 fusion peptide which 360 anchors in the host cell membrane to establish fusion. A model is shown in Figure 7 in which HIV-1 Env is 361 exposed and can bind to CD4, recruit coreceptor, and mediate viral membrane fusion. We propose that 362 treatment with NF449 results in binding of HIV-1 Env V1V2 which interferes with exposure of the binding site 363 for coreceptor engagement. The model demonstrates an effect in which NF449 may binding directly to V1V2 364 which may result in failure to recruit receptor ( Figure 7B1 ). Alternatively, NF449 may bind to another site, 365 resulting in conformational change that limits V1V2 access by PG9 ( Figure 7B2) . When NF449 or NF279 366 come in contact with HIV-1 Env at the V1V2 loop, a conformational change or steric hindrance prevents the 367 binding of HV-1 Env to recruit coreceptor, leading to a failure to complete HIV-1 fusion. When NF449 is added 368 together with PG9, there is abrogation of the inhibition caused by PG9 or NF449 alone. The inhibition profiles 369 for NF449 vary and will help to elucidate the development of targeted drugs that can serve to inhibit HIV-1 Env 370 and block HIV-1 viral membrane fusion. Future studies will address whether escape mutants of NF449-treated 371 cells develop Env mutations in the V1V2 site and if mutations in the V1V2 region are resistant to NF449 372 inhibition.
373 Based on this model, we propose that P2X1 antagonists may represent a novel adjunctive therapeutic 375 strategy whereby drug binding to HIV-1 Env can cause a conformational change or steric hindrance, 376 preventing coreceptor recruitment and viral membrane fusion that is negated in the presence of the anti-V1V2 377 antibody PG9. We conclude from these studies that P2X1 antagonists may represent potential HIV-1 378 therapeutic options that serve to inhibit cross-clade HIV-1 replication. Further studies will be necessary to 379 identify selective inhibitors that are amenable to pharmacologic development and define the precise 380 mechanism of inhibition. Regardless, these observations introduce important prospects for dually active 402 SF162 (pIRESSF162) env was constructed as previously described (73, 74) . HIV-1 NL-GI contains green 403 fluorescent protein (GFP) in place of nef, and nef expression is directed by a downstream internal ribosome 404 entry site (IRES) (28). HIV-1 NL-CI contains mCherry in place of nef, as above. PBMCs were infected with NL-405 GI/NL-CI, which contains the NL4-3 envelope (X4 tropic), or RHPA, which was constructed by insertion of the 406 R5-tropic B-clade primary envelope from pRHPA4259 clone 7 (SVPB14) into NL-GI (75) . The gene for the 407 RHPA clone was obtained, from B. H. Hahn and J. F. Salazar-Gonzalez (ARP). HIV-1 Gag-iCre is an HIV-1 408 clone carrying Cre recombinase as a Gag-internal gene fusion that releases active Cre into cells upon viral 409 entry activating a recombinatorial gene switch changing dsRed to GFP-expression (25). NL-CIΔCT was cloned 410 by generating a PCR fragment of the C-terminal Env from the NL-CIΔCT plasmid as described (36) .
411
Pseudoviruses were produced by co-transfecting 293T/17 cells with HIV-1 rev-and env-expressing plasmids 412 and the pNL4-3Δenv R-E-plasmid using the jetPEI transfection reagent (Polyplus-transfect SA). Supernatants 413 were harvested after 48 hours and clarified by high-speed centrifugation (Sorvall ST 40R Centrifuge, Thermo
414
Fisher Scientific) at 100,000 x g at 4°C for 2 hours and 0.45 μm filtration. Viral stocks were quantified by the 415 HIV-1 p24 antigen via enzyme-linked immunosorbent assay (ELISA) with coating antibody D7320, sheep anti-
416
HIV-1-p24 gag (Aalto Bio Reagents) as described previously (36) . Single-use aliquots were stored at −80°C. 
444
In HIV-1 fusion assays, donor cells labeled with eFluor 450 were detected in Alexa Fluor 405-A channel and 445 target cells that express dsRed were detected using Alexa Fluor 568-A channel. Transfer of gag-iCre from 446 donor to target cells was measured on the basis of activity of Cre Recombinase, which results in recombination 447 of Lox P sites switching the phenotype of the targets to GFP positive. This switch from dsRed to GFP was 448 measured using Alexa Fluor 568-A channel versus Alexa Fluor 488-A channel. All cells within a single 449 experiment were analyzed using the same instrument settings.
451
Productive infection assays. Target MT4 cells were infected in 96-well plates with HIV-1 NL-GI/NL-CI/NL-
452
CIΔCT/NL-CI-RHPA (1.62 ng p24 per well) to obtain up to 10% infection after 48 hours in the absence of 453 inhibitors. MT4 cells were pre-incubated with antagonists for 30 min at 37°C before infection with HIV-1. At 48 454 hours after infection, cells were fixed in 2% paraformaldehyde and infection was quantified via GFP or mCherry 455 fluorescence in flow cytometry. For the time-of-addition assay, P2X1 antagonists were added to MT4 cells at 456 the indicated time points of HPI with HIV-1 NL-CI (1.62 ng p24 per well), as previously described (29). At 48 457 hours after mixing, cells were stained and fixed in 2% paraformaldehyde for flow cytometry, as described 458 above. For coreceptor competition assays, MT4 cells were co-incubated with P2X antagonists and HIV-1 459 fusion antagonists for 30 min at 37°C before infection with HIV-1 NL-CI (1.62 ng p24 per well). At 48 hours 460 post infection, cells were stained and fixed in 2% paraformaldehyde for analysis via flow cytometry as 461 described above.
463
Virus Tropism in PBMCs. PBMCs were activated with PHA (4 μg/ml) and IL-2 (50 U/mL) for 3 days and 464 infected by spinoculation, as previously described (29). Briefly, 2.5 x 10 5 cells were incubated in the presence 465 or absence of indicated inhibitors in a 96-well flat bottom plate for 30 minutes at 37C then spun at 1,200 x g 466 for 99 minutes with 47.7 ng HIV-1 NL-CI or NL-CI RHPA. After overnight incubation at 37C, the culture 467 medium was replaced with complete RPMI containing IL-2 (50 U/ml) and 10 M AZT. At 48 h after 468 spinoculation, cells were stained and fixed in 2% paraformaldehyde for flow cytometry, as described above. 
471
was used as target cells and was generated by retroviral transduction with the pMSCV-loxP-dsRed-loxP-472 eGFP-Puro-WPRE vector (Addgene, plasmid 32702) (76) , which expresses a dsRed reporter flanked 473 by loxP sites followed by a Cre-activated enhanced GFP (eGFP) gene (76) . Jurkat (donor) cells were 474 transfected by nucleofection (Amaxa Biosystems) with 5 μg HIV-1 Gag-iCre DNA, cultured overnight in 475 antibiotic-free medium, and purified by Ficoll-Hypaque density gradient centrifugation. Target cells were 476 detected on the PE-Texas Red channel, and donor cells were preincubated separately with P2X1 antagonists 477 for 30 min at 37°C before mixing 1.25 × 10 5 cells at a ratio of approximately 1:1, co-cultured at 37°C for 48 478 hours, and fixed, as described previously (25).
480
Infectivity and Neutralization assay. Virus infectivity and neutralization was measured using a β-481 galactosidase-based luciferase assay (Promega) with TZM-bl target cells, as previously described (75) . Briefly, 482 serial dilutions of antagonists were added to the virus in 96-well plates (Costar) and incubated for the 483 designated time period at 37°C. TZM-bl cells were then added with or without DEAE-dextran (6.25μg/ml; 484 Sigma). After incubation for 48 hours, a luciferin-galactoside substrate (6-O-β-galactopyranosyl-luciferin) was 485 added. The cleavage of the substrate by β-galactosidase generates luminescent signals measured in RLUs.
486
Test and control conditions were tested in duplicate or triplicate. Assay controls included replicate wells of 487 TZM-bl cells alone (cell control) and TZM-bl cells with virus alone (virus control). Percent neutralization was 488 determined on the basis of virus control under the specific assay condition (e.g. 1 hour or 24 hours pre-489 incubation of virus without mAbs). The virus inputs were the diluted virus stocks yielding equivalent RLUs 490 (typically ~100,000 RLUs) under the different assay conditions.
492
Tetherin-high antibody binding assay. A cell-based assay for bNAb binding was used as previously 493 described (42) 
500
Statistical analysis and calculations. Comparisons were performed using GraphPad Prism 7, version 7.0d 501 (GraphPad Software). DMSO-treated controls were set to 100% and drug-treated conditions were expressed 502 as a percentage of control. Statistical analyses were performed on inhibition data that reached ≥50% with a 503 one-tailed student's t-test. A p value of less than 0.05 was considered statistically significant.
505
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741
Inhibitors were added at indicated concentrations to MT4 cells in the presence of HIV-1 NL-CI (X4-tropic). 
